Effector Function Improvement via Antibody Skeleton Engineering
Creative Biolabs provides an effector function improvement service that provides precise antibody engineering solutions to amplify their natural immune-stimulating capabilities. By meticulously tailoring the antibody's framework, we empower you to develop more potent and effective therapies, accelerating your journey from discovery to impactful treatments. Let us help you engineer antibodies with enhanced effector functions for superior clinical outcomes.
Overview
While antibody therapies have transformed healthcare, their optimal impact frequently relies on their capacity to robustly activate the immune system's effector pathways. These effector functions, including ADCC, ADCP, and CDC, play a vital role in eliminating targeted cells. Growing evidence underscores that enhancing these mechanisms can dramatically improve treatment efficacy, especially in cancer therapy. Therefore, fully leveraging the therapeutic capabilities of antibodies necessitates a focus on amplifying their effector functions.
Fig.1 Fc-effector functions enhancement through Fc engineering.1
Effector Function Improvement via Antibody Skeleton Engineering at Creative Biolabs
Creative Biolabs' effector function improvement service provides tailored solutions to optimize antibody effector functions. We offer a comprehensive approach, from initial consultation to final deliverables, ensuring a seamless and efficient process. Our tailored solutions are designed not just to meet your needs, but to anticipate potential obstacles and address them proactively. Specifically, our antibody skeleton engineering strategies involve several aspects, including but not limited to:
Our amino acid substitution service involves replacing one or more amino acid residues within the antibody sequence with different amino acids, such as E333 and K326 in human IgG. These substitutions can significantly impact the antibody's biological activity.
This service is designed to enhance the druggability and therapeutic potency of monoclonal antibodies by combining the strengths of different isotypes, such as IgG and IgA isotypes. By engineering 'cross-isotype' antibodies, Creative Biolabs helps clients achieve higher affinity or binding selectivity for FcγR, leading to improved target cell killing through ADCC, CDC, and ADCP.
Service Advantages
- Enhanced therapeutic efficacy
- Improved ADCC, ADCP, and CDC
- Increased target cell killing
- Optimized Fc receptor binding
- Tailored effector function profiles
Function Verified Related Sections
To thoroughly assess the impact of our engineering, the modified antibody variants are subjected to a detailed battery of in vitro functional assays, specifically designed to rigorously evaluate their effector functions. Beyond our engineering services, we also provide specialized testing capabilities to comprehensively analyze your engineered antibodies:
| Measuring the ability of the variants to mediate target cell killing by effector cells (e.g., NK cells). | |
| Assessing the enhancement in phagocytosis of target cells by macrophages. | |
| Evaluating the ability of the variants to trigger complement-mediated lysis of target cells. | |
| Quantifying the binding affinity of the variants to various Fc receptors (e.g., FcγRIIIa, FcγRIIa, FcγRIIIb, FcγRIIb, FcγRI, FcRn). | |
| Measuring the binding affinity to the complement component C1q. |
Why Choose Us
Creative Biolabs stands at the forefront of antibody engineering, specializing in enhancing effector functions through sophisticated antibody skeleton engineering. Our proven track record is built upon delivering tailored solutions, leveraging advanced technologies, and harnessing the knowledge of our experienced team. We offer a full spectrum of services, supported by published data, all aimed at accelerating your research and maximizing the success of your antibody therapeutics development. Contact us today to explore how our expertise in antibody skeleton engineering can drive your project forward.
Reference
- Van der Horst, Hilma J., et al. "Fc-engineered antibodies with enhanced Fc-effector function for the treatment of B-cell malignancies." Cancers 12.10 (2020): 3041. Distributed under Open Access License CC BY 4.0, without modification.
For Research Use Only.